News
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi gains EU approval for Cenrifki (tolebrutinib) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses, based on phase 3 studies. Cenrifki addresses SPMS disability progression -
-
-
-
PRESS RELEASE
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza publishes restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients as discontinued operations. Restatement includes updated income statement and key performance measures -
-
-